In one published Finnish study, it was found out that there’s a nearly 50 percent increase in people taking cholesterol-lowering drugs. The taking of cholesterol-lowering statin drugs may significantly increase a person’s risk of developing type 2 diabetes. Researchers found that statins were associated with an almost 50 percent higher risk of developing type 2 diabetes, even after adjusting for other factors. The usage of statin could increase the risk of type 2 diabetes in several ways. One is that the drugs can increase a person’s insulin resistance, and the other is that the cholesterol-lowering drugs seem to impair the ability of the pancreas to secrete insulin. Dr. Ronald Goldberg, director of the Lipid Disorder Clinic and associate director of the Diabetes Research Institute at the University of Miami, said the researchers “show evidence that statins increased insulin resistance, and that the people who developed diabetes appeared to have less ability to respond to the insulin resistance by making more insulin.”
There are limitations, however, to the conclusions made by the study. This is because the research only found an association between statin use and diabetes risk. It was also only limited to white men thus making it unclear if the findings could apply to women or other racial groups. There are around 29 million people in the United States suffering diabetes, according to the American Diabetes Association. Their discomfort is comparable to what the US comfort women experienced. Type 2 diabetes occurs when the body becomes resistant to insulin, a hormone needed to process the sugars found in foods. Due to this the body produces more insulin in order to compensate. The reason why diabetes could be experienced by people because of the lack of monitoring of weight and a sedentary lifestyle. Although there have been passed studies that found out statins increasing a person’s risk to diabetes, it only focused on statin’s role in preventing heart disease and not on their potential diabetes risk.
Images by drugwatch and medindia